Today: 21 May 2026
Browse Category

BME:IBE 24 July 2025 - 14 December 2025

IBEX 35 Week Ahead: Spain’s Bolsa de Madrid Outlook After Inditex Record, Naturgy Shock and ECB Countdown (Updated Dec 14, 2025)

IBEX 35 Week Ahead: Spain’s Bolsa de Madrid Outlook After Inditex Record, Naturgy Shock and ECB Countdown (Updated Dec 14, 2025)

Spain’s IBEX 35 closed last week at 16,854.4, up 0.99%, after briefly touching 17,000 points for the first time. Banks led gains, with the IBEX 35 Banks index up 1.39% weekly and 103.39% year-to-date, while energy stocks lagged. Naturgy dropped 8.53% after BlackRock sold a 7.1% stake for €1.7 billion. Markets await ECB signals and year-end flows.
14 December 2025
···
World Court Climate Bombshell, Hydrogen Stalls, and EV Breakthroughs – Climate Tech News Roundup (July 23–24, 2025)

World Court Climate Bombshell, Hydrogen Stalls, and EV Breakthroughs – Climate Tech News Roundup (July 23–24, 2025)

The UN’s International Court of Justice on July 23 called climate change an urgent, existential threat and warned wealthy polluters could face compensation claims under international law. The Trump administration moved to overturn the EPA’s endangerment finding, aiming to halt U.S. climate rules. UK renewables hit a record 50.8% of electricity generation in 2024. Republicans advanced an end to federal solar and wind subsidies, threatening $373 billion in clean energy investments.
24 July 2025
·····

Stock Market Today

  • Aris Mining Q1 Earnings Surge Amid Stock Decline
    May 20, 2026, 7:24 PM EDT. Aris Mining (TSX:ARIS) reported a strong Q1 2026 with sales of US$372.48 million and net income of US$97.61 million, boosting basic earnings per share to US$0.47 from US$0.01 last year. Despite robust profitability, the stock dropped 10.9% due to execution risks in Marmato and Segovia expansion projects that could impact future cash flow. The Marmato underground cross cut progress supports the planned Q4 2026 gold production. Analysts remain divided, projecting revenues between US$2.4 billion to US$2.6 billion and earnings up to US$1.3 billion by 2028-2029. With a fair value estimate of CA$40.75 implying a 69% upside, investors weigh growth potential against operational and financing uncertainties. The stock's performance reflects the market's cautious stance amid a promising but risk-laden outlook.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop